These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 37913652)

  • 1. Cisplatin-activated ERβ/DCAF8 positive feedback loop induces chemoresistance in non-small cell lung cancer via PTEN/Akt axis.
    Hu Y; Xu Y; Zhang T; Han Q; Li L; Liu M; Li N; Shao G
    Drug Resist Updat; 2023 Nov; 71():101014. PubMed ID: 37913652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deregulation of lncRNA-AC078883.3 and microRNA-19a is involved in the development of chemoresistance to cisplatin via modulating signaling pathway of PTEN/AKT.
    Xing S; Qu Y; Li C; Huang A; Tong S; Wu C; Fan K
    J Cell Physiol; 2019 Dec; 234(12):22657-22665. PubMed ID: 31111480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-25-3p promotes cisplatin resistance in Non-small-cell lung carcinoma (NSCLC) through adjusting PTEN/PI3K/AKT route.
    Sun B; Hu N; Cong D; Chen K; Li J
    Bioengineered; 2021 Dec; 12(1):3219-3228. PubMed ID: 34266345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.
    Lindberg K; Helguero LA; Omoto Y; Gustafsson JÅ; Haldosén LA
    Breast Cancer Res; 2011 Apr; 13(2):R43. PubMed ID: 21492444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutathione Peroxidase 1 Promotes NSCLC Resistance to Cisplatin via ROS-Induced Activation of PI3K/AKT Pathway.
    Chen B; Shen Z; Wu D; Xie X; Xu X; Lv L; Dai H; Chen J; Gan X
    Biomed Res Int; 2019; 2019():7640547. PubMed ID: 31032363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TRIM59 knockdown blocks cisplatin resistance in A549/DDP cells through regulating PTEN/AKT/HK2.
    He R; Liu H
    Gene; 2020 Jul; 747():144553. PubMed ID: 32165307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GAS5 knockdown reduces the chemo-sensitivity of non-small cell lung cancer (NSCLC) cell to cisplatin (DDP) through regulating miR-21/PTEN axis.
    Cao L; Chen J; Ou B; Liu C; Zou Y; Chen Q
    Biomed Pharmacother; 2017 Sep; 93():570-579. PubMed ID: 28686971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-204 reduces cisplatin resistance in non-small cell lung cancer through suppression of the caveolin-1/AKT/Bad pathway.
    Huang G; Lou T; Pan J; Ye Z; Yin Z; Li L; Cheng W; Cao Z
    Aging (Albany NY); 2019 Apr; 11(7):2138-2150. PubMed ID: 30981205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CLPTM1L induces estrogen receptor β signaling-mediated radioresistance in non-small cell lung cancer cells.
    Li H; Che J; Jiang M; Cui M; Feng G; Dong J; Zhang S; Lu L; Liu W; Fan S
    Cell Commun Signal; 2020 Sep; 18(1):152. PubMed ID: 32943060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer-associated fibroblast-derived exosomal microRNA-20a suppresses the PTEN/PI3K-AKT pathway to promote the progression and chemoresistance of non-small cell lung cancer.
    Shi L; Zhu W; Huang Y; Zhuo L; Wang S; Chen S; Zhang B; Ke B
    Clin Transl Med; 2022 Jul; 12(7):e989. PubMed ID: 35857905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exosomal Transfer Of Cisplatin-Induced miR-425-3p Confers Cisplatin Resistance In NSCLC Through Activating Autophagy.
    Ma Y; Yuwen D; Chen J; Zheng B; Gao J; Fan M; Xue W; Wang Y; Li W; Shu Y; Xu Q; Shen Y
    Int J Nanomedicine; 2019; 14():8121-8132. PubMed ID: 31632022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
    Xu JL; Wang ZW; Hu LM; Yin ZQ; Huang MD; Hu ZB; Shen HB; Shu YQ
    Asian Pac J Cancer Prev; 2012; 13(5):2157-62. PubMed ID: 22901187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-181 regulates cisplatin-resistant non-small cell lung cancer via downregulation of autophagy through the PTEN/PI3K/AKT pathway.
    Liu J; Xing Y; Rong L
    Oncol Rep; 2018 Apr; 39(4):1631-1639. PubMed ID: 29484437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-29c reduces the cisplatin resistance of non-small cell lung cancer cells by negatively regulating the PI3K/Akt pathway.
    Sun DM; Tang BF; Li ZX; Guo HB; Cheng JL; Song PP; Zhao X
    Sci Rep; 2018 May; 8(1):8007. PubMed ID: 29789623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of Linc00173 increases BCL2 mRNA stability via the miR-1275/PROCA1/ZFP36L2 axis and induces acquired cisplatin resistance of lung adenocarcinoma.
    Tao X; Li Y; Fan S; Wu L; Xin J; Su Y; Xian X; Huang Y; Huang R; Fang W; Liu Z
    J Exp Clin Cancer Res; 2023 Jan; 42(1):12. PubMed ID: 36627670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of PI3K/Akt pathway by G protein-coupled receptor 37 promotes resistance to cisplatin-induced apoptosis in non-small cell lung cancer.
    Liu H; Zhu Y; Niu H; Jie J; Hua S; Bai X; Wang S; Song L
    Cancer Med; 2023 Oct; 12(19):19777-19793. PubMed ID: 37732632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells.
    Guo J; Jin D; Wu Y; Yang L; Du J; Gong K; Chen W; Dai J; Miao S; Xi S
    EBioMedicine; 2018 Sep; 35():204-221. PubMed ID: 30146342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.
    Pu X; Hildebrandt MA; Lu C; Lin J; Stewart DJ; Ye Y; Gu J; Spitz MR; Wu X
    Lung Cancer; 2011 Jan; 71(1):82-8. PubMed ID: 20447721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reduction.
    Wu DW; Lee MC; Hsu NY; Wu TC; Wu JY; Wang YC; Cheng YW; Chen CY; Lee H
    Oncogene; 2015 May; 34(19):2505-15. PubMed ID: 24998847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
    Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y
    Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.